Bettina Nauli, Ph.D. – VP Central & Northern Europe at Alexion, AstraZeneca Rare Disease – AstraZeneca | LinkedIn
Alexion Pharmaceuticals
Alexion dodges Soliris biosimilar bullet—for now—with Amgen patent settlement | Fierce Pharma
Alexion asked AstraZeneca to up its buyout offer multiple times—almost costing it a deal in the process | Fierce Pharma
Alexion
Alexion clears acquisition hurdles; Thetis gets $1.9M grant; Precipio signs European distribution deal | New Haven BIZ
alexion – EJP RD – European Joint Programme on Rare Diseases
Alexion
UK Says 'Not So Fast' on AstraZeneca's $39 Billion Alexion Acquisition | BioSpace
UK regulator reviewing AstraZeneca's $39 bln Alexion buyout | Reuters
Alexion will invest €450 million to expand to Dublin - Labiotech.eu
Alexion Says Senior Management Improperly Pressured Staff to Boost Sales - WSJ
AstraZeneca stock tumbles as Alexion shares soar after companies agree on takeover deal - MarketWatch
European marketing authorisation for Kanuma™
AstraZeneca gets EU clearance on Alexion - P.M. News
AstraZeneca Receives European Commission Approval to Acquire Alexion for $39 billion | Healthcare Business Club
Alexion Pharmaceuticals: Revising My Valuation (NASDAQ:ALXN) | Seeking Alpha
Alexion
AstraZeneca's Alexion to amplify the voices of rare disease, with a focus on diversity in diagnosis | Fierce Pharma
Alexion Wins Expanded Approval for Blockbuster Drug Soliris | BioSpace
Alexion Pharmaceuticals - Crunchbase Company Profile & Funding
AstraZeneca's acquisition of Alexion cleared by European Commission - NewsnReleases
Alexion
